Pfizer reports positive data from trial of gene therapy for haemophilia A
Pfizer has reported positive data from the Phase III AFFINE clinical trial of investigational gene therapy, giroctocogene fitelparvovec, to treat…
Pfizer has reported positive data from the Phase III AFFINE clinical trial of investigational gene therapy, giroctocogene fitelparvovec, to treat…
Multiple myeloma is the third most common blood malignancy globally. It accounts for 2% of all diagnoses and 1% of…
Sanofi has reported that its ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] showed promise in the Phase III XTEND-Kids study…
CSL Behring has announced the treatment of two patients with HEMGENIX (etranacogene dezaparvovec) gene therapy for haemophilia B, an inherited…
Johnson & Johnson (J&J) has reported positive second interim analysis data from the Phase III CARTITUDE-4 clinical trial of CARVYKTI (ciltacabtagene…
The European Commission has granted marketing authorisation to Sobi’s Altuvoct (efanesoctocog alfa) for the treatment and prevention of bleeds and…
Pfizer has announced findings from the Phase II MagnetisMM-3 clinical trial of ELREXFIO (elranatamab-bcmm) in patients with relapsed or refractory…
HUTCHMED has announced the initiation of a Phase I clinical trial of its menin inhibitor, HMPL-506, to potentially treat patients…
AbbVie has treated the first subject in the Phase III CERVINO clinical trial of its investigational product ABBV-383 to treat…
Danish pharmaceutical company Novo Nordisk has reported headline results from FRONTIER II, a Phase IIIa trial of subcutaneous Mim8 in…